Eli Lilly and Company (BMV:LLY)

Market Cap	12.96T
Revenue (ttm)	1.00T
Net Income (ttm)	227.00B
Shares Out	n/a
EPS (ttm)	251.19
PE Ratio	57.08
Forward PE	30.35
Dividend	111.06 (0.77%)
Ex-Dividend Date	May 16, 2025

Volume	4,542
Average Volume	1,050
Open	14,425
Previous Close	14,297
Day's Range	14,425 - 14,530
52-Week Range	13,700 - 19,261
Beta	0.39
RSI	46.09
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD